As Cannara Biotech Inc. prepares to announce its fiscal Q3 2026 results, investors are eager to see if the company can meet or exceed its earnings estimates.
Cannara Biotech Inc. (LOVE.TO) is set to release its fiscal Q3 2026 financial results on July 15, 2026, before the market opens. The company has faced challenges in the past, having missed earnings estimates in its most recent quarter. With an EPS estimate of $0.03, all eyes will be on Cannara as it seeks to turn its earnings trajectory around.
Recent earnings trend
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Cannara Biotech Inc.
LOVE.TO
LOVE.TO
Cannara Biotech Inc.
WealthAwesomeMarket cap
$179.78M
P/E
16.5x
52W high
$2.05
52W low
$1.55
1W change
-3.24%
Beta
0.35
Analyst Price Targets
Based on analyst covering LOVE
Wall Street analysts forecast LOVE stock price to rise 78.1% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$3.19
+78.1% Upside
Current Price
C$1.79
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on LOVE's historical volatility
30-Day Vol
36.4%
Annualized
90-Day Vol
33.7%
Annualized
Trend (90d)
+2.4%
Annualized drift
90d Mean
C$1.81
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$1.80 | C$1.58 – C$2.04 |
| 60 trading days | C$1.80 | C$1.51 – C$2.15 |
| 90 trading days | C$1.81 | C$1.45 – C$2.24 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Analyst coverage: 1 analyst(s) cover this name; upcoming EPS consensus is available.
| Fiscal period | Report date | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| 2026-05-31 | 2026-07-15 | — | 0.0300 | — |
| 2026-02-28 | 2026-04-14 | 0.0200 | 0.0400 | -50.0% |
| 2025-11-30 | 2025-11-30 | — | 0.0100 | — |
Investor takeaway: With low analyst coverage and a history of missing estimates, Cannara's upcoming earnings report presents both risks and opportunities for investors. The company's recent strategic moves, including new technology rights and acquisitions, could influence its performance.
EPS Estimate: $0.03
Cannara's EPS estimate of $0.03 marks a decrease from the previous estimate of $0.04, reflecting a cautious outlook from analysts.
Bull case
If Cannara can effectively use its recent acquisition of Medican Organic Inc. and the exclusive rights to innovative technology, it might achieve revenue growth that exceeds expectations, potentially leading to a positive earnings surprise.
Bear case
Given Cannara's history of missing earnings estimates and the limited analyst coverage, there’s a risk that the company may not meet expectations again, which could negatively affect investor sentiment.
Advertisement
